Scivita Medical Technology has entered a strategic agreement with Boston Scientific for its single-use percutaneous choledochoscope.
The companies intend to establish a long-term business collaboration, as well as a distribution agreement for the commercialisation, marketing and promotion of Scivita’s single-use percutaneous choledochoscope in China.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Scivita Medical expects this collaboration to further broaden the market penetration of its percutaneous choledochoscope, which is part of the company’s comprehensive product offering of single-use videoscopes, reusable endoscopes, and related systems and equipment.
The percutaneous choledochoscope penetration rate in China is expected to increase, benefiting more hospitals and patients, due to the collaboration with Boston Scientific.
Scivita Medical said in a statement: “This is another important initiative for Scivita Medical in establishing its vision of becoming a global company, and another milestone following its strategic cooperation with Fujifilm for the European market.
“I believe this strategic cooperation with some of the world’s leading medical technology companies and our company will accelerate the process of bringing China’s medical innovations to the world.”
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataIt also noted that the global single-use videoscope market is growing quickly as a result of increased demands to mitigate cross-contamination risks and hospital-acquired diseases, mainly amid the outbreak of Covid-19.
Going forward, the company intends to further strengthen its innovation, as well as improve market penetration by providing unique products for physicians and patients across the world.
